查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712497

日本CAR-T细胞疗法市集—2025-2033

Japan CAR-T Cell Therapies Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年日本 CAR-T 细胞疗法市场规模达到 3.46 亿美元，预计到 2033 年将达到 13.5015 亿美元，在 2025-2033 年预测期内的复合年增长率为 16.3%。

CAR-T 细胞疗法，即嵌合抗原受体 T 细胞疗法，是一种主要用于癌症治疗的先进免疫疗法。它涉及对患者的 T 细胞（一种免疫细胞）进行改造，透过修饰它们来表达嵌合抗原受体 (CAR)，从而使这些细胞能够识别和攻击特定的癌细胞。 CAR-T 细胞疗法对某些血癌特别有效，例如急性淋巴性白血病 (ALL) 和某些类型的淋巴瘤。

然而，目前正在进行研究以使这种方法适用于实体肿瘤，实体肿瘤面临不同的挑战，例如更具抑制性的肿瘤微环境可能会限制 CAR-T 细胞的有效性。 CAR-T 细胞疗法的需求正在迅速增长，这得益于其治疗晚期血癌的潜力及其提供个人化治疗结果的能力。

市场动态：

驾驶员和约束装置

血液系统癌症发生率上升

日本多发性骨髓瘤、白血病和淋巴瘤等血液系统癌症发生率的上升预计将显着推动该国 CAR-T 细胞治疗市场的成长。随着日本人口老化，这些血液相关癌症的发生率一直在稳步上升，对先进且有效的治疗方案的需求也越来越大。例如，根据国际癌症研究机构提供的资料，2022年日本报告了约6,988例多发性骨髓瘤新病例。预计到2025年，这数字将达到7,350例。此外，预计到2030年日本多发性骨髓瘤发生率将达7,535。

传统疗法在復发或难治性病例中通常收效有限，这增加了对 CAR-T 细胞疗法等创新解决方案的需求。这种尖端方法涉及重新编程患者的免疫细胞以瞄准和摧毁癌细胞，为已经用尽标准治疗方法的患者带来了新的希望。随着人们认识的提高和监管支持的加强，正如最近批准的 CARVYKTI 一样，日本有望成为亚太地区 CAR-T 细胞疗法的主要市场。因此，上述因素正在推动市场成长。

治疗费用高昂

CAR-T 细胞疗法的高成本限制了患者和医疗保健系统的可近性和可负担性，严重阻碍了其市场成长。成本障碍限制了患者获得治疗的机会，特别是在没有全面报销框架的国家，并且限制了该疗法的市场渗透。由于缺乏长期成本效益资料，许多医疗保健提供者和保险公司不愿承保 CAR-T 细胞疗法，因此儘管该疗法具有临床疗效，但仍限制了其采用。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按治疗类型分类的片段
  • 依药物类型分类的片段
  • 目标抗原片段
  • 按应用程式截取的程式码片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 血液系统癌症发生率上升
      • 个人化治疗需求不断成长
    • 限制
      • 治疗费用高昂
      • 严格的规范架构
    • 机会
      • 临床研究数量不断增加
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 北美监管与报销格局
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：CAR-T细胞疗法市场（依疗法类型划分）

  • 自体CAR-T细胞疗法
  • 同种异体CAR-T细胞疗法

第六章：CAR-T细胞疗法市场（依药物类型）

  • 阿贝克玛
  • 布雷扬齐
  • 卡尔维克蒂
  • 特卡图斯
  • 基姆里亚
  • 耶斯卡塔

第七章：CAR-T细胞疗法市场（以标靶抗原）

  • CD19
  • BCMA（B细胞成熟抗原）
  • CD20
  • CD22
  • CD30
  • 其他的

第 8 章：CAR-T 细胞疗法市场（按应用）

  • 急性淋巴母细胞白血病（ALL）
  • 非何杰金氏淋巴瘤
  • 慢性淋巴球白血病
  • 多发性骨髓瘤（MM）
  • 滤泡性淋巴瘤
  • 其他的

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Gilead Sciences, Inc.
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Bristol Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • 宝生物公司

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: PH9491

The Japan CAR-T cell therapies market reached US$ 346.00 million in 2024 and is expected to reach US$ 1,350.15 million by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

CAR-T cell therapy, or Chimeric Antigen Receptor T-cell therapy, is an advanced immunotherapy used primarily in cancer treatment. It involves engineering a patient's T cells, a type of immune cell, by modifying them to express a chimeric antigen receptor (CAR) that allows these cells to recognize and attack specific cancer cells. CAR-T cell therapy has been particularly effective for certain blood cancers, such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma.

However, research is ongoing to adapt this approach for solid tumors, which have different challenges, like a more suppressive tumor microenvironment that can limit CAR-T cell effectiveness. The demand for CAR-T cell therapy is growing rapidly, driven by its potential to treat advanced blood cancers and its ability to deliver personalized treatment outcomes.

Market Dynamics: Drivers & Restraints

Rising Incidence of Hematological Cancers

The rising incidence of hematological cancers in Japan, such as multiple myeloma, leukemia, and lymphoma, is expected to significantly drive the growth of the country's CAR-T cell therapy market. As Japan's population continues to age, the prevalence of these blood-related cancers has been steadily increasing, creating a greater need for advanced and effective treatment options. For instance, according to the data provided by the International Agency for Research on Cancer, around 6,988 new cases of multiple myeloma were reported in Japan in 2022. By 2025, the number is expected to reach 7,350. Also, it is estimated that the incidence of multiple myeloma in Japan is expected to reach 7,535 by 2030.

Traditional therapies often have limited success in relapsed or refractory cases, which is raising the demand for innovative solutions like CAR-T cell therapy. This cutting-edge approach, which involves reprogramming a patient's immune cells to target and destroy cancer cells, offers new hope for patients who have exhausted standard treatments. As awareness grows and regulatory support strengthens, as seen with recent approvals like CARVYKTI, Japan is poised to become a key market for CAR-T cell therapies in the Asia-Pacific region. Thus, the above factors are driving the market growth.

High Costs of Therapy

The high cost of CAR-T cell therapy significantly hampers its market growth by limiting accessibility and affordability for patients and healthcare systems. The cost barrier restricts patient access, especially in countries without comprehensive reimbursement frameworks, and limits the therapy's market penetration. Many healthcare providers and insurers hesitate to cover CAR-T cell therapy due to the lack of long-term cost-benefit data, thus constraining its adoption despite clinical efficacy.

Segment Analysis

The Japan CAR-T cell therapies market is segmented based on the therapy type, drug type, target antigen, and application.

Multiple myeloma in the application segment is expected to dominate the CAR-T cell therapies market

Multiple myeloma is projected to lead the application segment of Japan's CAR-T cell therapy market, driven by the rising number of cancer cases, increasing approval and launch activities from key industry players. For instance, in September 2022, Legend Biotech Corporation, a global biotechnology company focused on developing, manufacturing, and commercializing innovative therapies for life-threatening diseases, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) had approved CARVYKTI (ciltacabtagene autoleucel). This BCMA-targeted CAR-T cell therapy is now approved for the treatment of adult patients with relapsed or refractory multiple myeloma.

Additionally, in December 2023, Bristol Myers Squibb's idecabtagene vicleucel was approved in Japan for patients with relapsed or refractory multiple myeloma who had received at least two prior lines of therapy. The approval was supported by results from the phase 3 KarMMA-3 trial, which showed significant improvements in progression-free survival and objective response rates compared to standard therapies.

These developments underscore the growing focus on multiple myeloma within Japan's CAR-T therapy market. The increasing availability of approved CAR-T treatments is expected to meet the rising demand for effective therapies, solidifying multiple myeloma as a dominant application area in this market segment.

Competitive Landscape

The market players in the CAR-T cell therapies market are Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson Services, Inc., and Novartis AG, among others.

Key Developments

  • In April 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
  • In January 2024, Bristol Myers Squibb announced three regulatory acceptances from the U.S. Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare (MHLW) for Breyanzi (lisocabtagene maraleucel).
  • In April 2023, Takara Bio Inc. submitted a Clinical Trial Application (CTA) to Health Canada and the receipt of the No Objection Letter to initiate a Phase I/Ib clinical trial for CD19 JAK/STAT CAR-T therapy (TBI-2001). Once the necessary steps are taken, the investigator-initiated clinical trial will be started for patients with CD19-positive B-cell lymphoma.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan CAR-T cell therapies market report would provide approximately 42 tables, 33 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Therapy Type
  • 2.4. Snippet by Drug Type
  • 2.5. Snippet by Target Antigen
  • 2.6. Snippet by Application

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Incidence of Hematological Cancers
      • 3.1.1.2. Growing Demand for Personalized Therapies
    • 3.1.2. Restraints
      • 3.1.2.1. High Costs of Therapy
      • 3.1.2.2. Stringent Regulatory Framework
    • 3.1.3. Opportunity
      • 3.1.3.1. Rising Number of Clinical Studies
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. North America Regulatory and Reimbursement Landscape
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. CAR-T cell therapies Market, By Therapy Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 5.1.2. Market Attractiveness Index, By Therapy Type
  • 5.2. Autologous CAR-T Cell Therapy*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Allogeneic CAR-T Cell Therapy

6. CAR-T cell therapies Market, By Drug Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 6.1.2. Market Attractiveness Index, By Drug Type
  • 6.2. Abecma*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Breyanzi
  • 6.4. Carvykti
  • 6.5. Tecartus
  • 6.6. Kymriah
  • 6.7. Yescarta

7. CAR-T cell therapies Market, By Target Antigen

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
    • 7.1.2. Market Attractiveness Index, By Target Antigen
  • 7.2. CD19*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. BCMA (B-cell maturation antigen)
  • 7.4. CD20
  • 7.5. CD22
  • 7.6. CD30
  • 7.7. Others

8. CAR-T cell therapies Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Acute Lymphoblastic Leukemia (ALL)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Non-Hodgkin Lymphoma
  • 8.4. Chronic Lymphocytic Leukemia
  • 8.5. Multiple Myeloma (MM)
  • 8.6. Follicular Lymphoma
  • 8.7. Others

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

Established Players

  • 10.1. Gilead Sciences, Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Bristol Myers Squibb Company
  • 10.3. Johnson & Johnson Services, Inc.
  • 10.4. Novartis AG

Emerging Players

  • 10.5. Takara Bio Inc

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us